Advertisement

Digestive Diseases and Sciences

, Volume 53, Issue 3, pp 830–835 | Cite as

Terlipressin and Albumin in Patients with Cirrhosis and Type I Hepatorenal Syndrome

  • Sergio Neri
  • Davide Pulvirenti
  • Mariano Malaguarnera
  • Bruno M. Cosimo
  • Gaetano Bertino
  • Luca Ignaccolo
  • Sebasiano Siringo
  • Pietro Castellino
Original Paper

Abstract

Purpose: Hepatorenal syndrome (HRS) is a pre-renal-like dysfunction that generally onsets in cirrhotic patients presenting ascites. We investigated the improvement of renal function in subjects with hepatorenal syndrome after terlipressin administration and the survival times after this treatment. Fifty-two patients affected by cirrhosis, with diagnosis of hepatorenal syndrome were treated with intravenous terlipressin plus albumin (group A) or with albumin alone (group B). Liver and renal function, plasma renin activity, and aldosterone plasma levels were monitored. Results: Patients from group A showed a significant improvement (p < 0.001) of renal function valued by creatinine rate compared with the results obtained in group B. The probability of survival was higher in the group A (p < 0.0001). Conclusions: Our results seem to confirm that the administration of terlipressin plus albumin improves renal function in patients with cirrhosis and type I HRS and that a reversal of hepatorenal syndrome is strongly associated with improved survival.

Keywords

Hepatorenal syndrome Liver cirrhosis Terlipressin Ascites Diuretics Albumin 

References

  1. 1.
    Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Scholmerich J (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23:164–176PubMedCrossRefGoogle Scholar
  2. 2.
    Angeli P (2004) Prognosis of hepatorenal syndrome—has it changed with current practice? Aliment Pharmacol Ther 20(3):44–46PubMedCrossRefGoogle Scholar
  3. 3.
    Barada K (2004) Hepatorenal syndrome: pathogenesis and novel pharmacological targets. Curr Opin Pharmacol 4:189–197PubMedCrossRefGoogle Scholar
  4. 4.
    Guevara M, Rodés J (2005) Hepatorenal syndrome. Int J Biochem Cell Biol 37:22–26PubMedCrossRefGoogle Scholar
  5. 5.
    Ginès P, Guevara N, Perez-Villa F (2004) Management of hepatorenal syndrome: another piece of the puzzle. Hepatology 40:16–18PubMedCrossRefGoogle Scholar
  6. 6.
    Gardenas A (2005) Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am J Gastroenterol 100:460–467CrossRefGoogle Scholar
  7. 7.
    Gines P, Guevara M, Arroyo V, Rodes J (2003) Hepatorenal syndrome. Lancet 362:1819–1827PubMedCrossRefGoogle Scholar
  8. 8.
    Therapondos G, Stanley AJ, Hayes PC (2004) Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: pilot study. J Gastroenterol Hepatol 19:73–77PubMedCrossRefGoogle Scholar
  9. 9.
    Antoniades C, Auzinger G (2003) Terlipressin and albumin for the hepatorenal syndrome. Hepatology 37:946PubMedCrossRefGoogle Scholar
  10. 10.
    Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barriere E, Lebrec D, Valla DC, Moreau R (2002) Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol 17:882–888PubMedCrossRefGoogle Scholar
  11. 11.
    Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jimenez W, Arroyo W, Rodes J (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36:941–948PubMedGoogle Scholar
  12. 12.
    Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK (2003) Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18:152–156PubMedCrossRefGoogle Scholar
  13. 13.
    Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, Bataller R, Mas A, Navasa M, Arroyo V, Rodes J (2000) Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33:43–48PubMedCrossRefGoogle Scholar
  14. 14.
    Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL,Roudot-Thoraval F, Mallat A, Dhumeaux D (2002) Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 362:374–380CrossRefGoogle Scholar
  15. 15.
    Moreau R, Assellah T, Condat B, de Kerguenec C, Pessione F, Bernard B, Poynard T, Binn M, Grange JD, Valla D, Lebrec D (2002) Comparison of the effects of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomized pilot study. Gut 50:90–94PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Sergio Neri
    • 1
  • Davide Pulvirenti
    • 1
  • Mariano Malaguarnera
    • 2
  • Bruno M. Cosimo
    • 3
  • Gaetano Bertino
    • 3
  • Luca Ignaccolo
    • 1
  • Sebasiano Siringo
    • 4
  • Pietro Castellino
    • 1
  1. 1.Department of Internal Medicine and Systemic Diseases, Liver Operative UnitCatania University PolyclinicCataniaItaly
  2. 2.Department of Internal Medicine and Geriatrics, Cannizzaro HospitalUniversity of CataniaCataniaItaly
  3. 3.Department of Internal Medicine and Systemic Diseases, Liver Operative Unit, S. Marta HospitalUniversity of CataniaCataniaItaly
  4. 4.Internal MedicineGaribaldi HospitalCataniaItaly

Personalised recommendations